Table 1.
Demographics and baseline clinical parameters of the study population and of the groups with and without HeartLogic alerts during the observation period
| Parameter |
Total N = 58 |
Alerts N = 16 |
No alerts N = 42 |
P |
|---|---|---|---|---|
| Male gender, n (%) | 47 (81) | 13 (81) | 34 (80) | 0.980 |
| Age, years | 71 ± 9 | 72 ± 11 | 70 ± 9 | 0.773 |
| Ischaemic aetiology, n (%) | 21 (37) | 7 (44) | 14 (33) | 0.461 |
| QRS duration, ms | 153 ± 25 | 147 ± 24 | 156 ± 25 | 0.340 |
| NYHA class | ||||
| Class I, n (%) | 2 (4) | 1 (6) | 1 (2) | 0.025 |
| Class II, n (%) | 29 (50) | 4 (25) | 26 (62) | |
| Class III, n (%) | 26 (44) | 11 (69) | 14 (33) | |
| Class IV, n (%) | 1 (2) | 0 (0) | 1 (2) | |
| LV ejection fraction, % | 30 ± 8 | 26 ± 6 | 31 ± 8 | 0.016 |
| AF history, n (%) | 23 (40) | 9 (56) | 14 (34) | 0.111 |
| Diabetes, n (%) | 18 (30) | 9 (53) | 9 (22) | 0.010 |
| COPD, n (%) | 9 (17) | 3 (21) | 6 (16) | 0.675 |
| Chronic kidney disease, n (%) | 14 (24) | 6 (36) | 8 (20) | 0.142 |
| Hypertension, n (%) | 48 (82) | 13 (80) | 35 (83) | 0.851 |
| β‐Blocker use, n (%) | 55 (94) | 13 (84) | 42 (100) | 0.004 |
| ACE‐inhibitor use, n (%) | 32 (55) | 10 (62) | 22 (53) | 0.489 |
| Diuretic use, n (%) | 53 (92) | 16 (100) | 37 (87) | 0.149 |
| Antiarrhythmic use, n (%) | 10 (17) | 3 (18) | 7 (16) | 0.851 |
| Ivabradine use, n (%) | 6 (10) | 0 (0) | 6 (14) | 0.110 |
| Primary prevention, n (%) | 55 (95) | 14 (87) | 41 (97) | 0.120 |
ACE, angiotensin‐converting enzyme; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; LV, left ventricular; NYHA, New York Heart Association.